



NEWS RELEASE

## pellepharm to present at piper jaffray healthcare conference

2018-11-21

SAN FRANCISCO--(**BUSINESS WIRE**)--PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that Sanuj K. Ravindran, M.D., chief executive officer and president, will present at the Piper Jaffray Healthcare Conference on Tuesday, November 27, at 12:30 p.m. EST in New York.

A live webcast of the presentation can be accessed on the company's website at [www.pellepharm.com](http://www.pellepharm.com). A replay of the webcast will be archived on the PellePharm website for at least two weeks following the presentation.

### About PellePharm

Founded by world leaders in hedgehog pathway signaling, PellePharm, a BridgeBio Company, is committed to targeting rare, genetic dermatological diseases, including Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC), at their source. PellePharm's mission is to improve the quality of life for those suffering from Gorlin Syndrome and High Frequency BCC by providing an easy-to-use topical gel that eliminates the need for regular, painful surgeries. Patidegib topical gel is a first-in-class topical formulation of a proprietary hedgehog inhibitor.

CONTACTS

Lauren Barbiero

W2O pure

(646) 564-2156

**lbarbiero@purecommunications.com**